![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster
|
|
|
Reported by Jules Levin
CROI SF 2010 Feb 16-19
Calvin Cohen1, David Shamblaw2, Peter Ruane3, Richard Elion4, Edwin DeJesus5, HuiC. Liu6, LijieZhong6, David Warren6, Brian P. Kearney6, and Steven L. Chuck6
1Community Research Initiative of New England, Boston, MA; 2San Diego, CA;
3Los Angeles, CA; 4Whitman Walker Clinic, Washington, D.C.;
5Orlando Immunology Center, Orlando, FL; and 6Gilead Sciences, Foster City,
![image002.gif](../images/021810/101810-1/image002.gif)
![image004.gif](../images/021810/101810-1/image004.gif)
![image006.gif](../images/021810/101810-1/image006.gif)
![image008.gif](../images/021810/101810-1/image008.gif)
![image010.gif](../images/021810/101810-1/image010.gif)
![image012.gif](../images/021810/101810-1/image012.gif)
![image014.gif](../images/021810/101810-1/image014.gif)
![image016.gif](../images/021810/101810-1/image016.gif)
![image018.gif](../images/021810/101810-1/image018.gif)
![image020.gif](../images/021810/101810-1/image020.gif)
![image022.gif](../images/021810/101810-1/image022.gif)
![image024.gif](../images/021810/101810-1/image024.gif)
![image026.gif](../images/021810/101810-1/image026.gif)
![image028.gif](../images/021810/101810-1/image028.gif)
![image030.gif](../images/021810/101810-1/image030.gif)
![image032.gif](../images/021810/101810-1/image032.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|